Thin melanoma and late recurrences: It is never too thin and never too late

Antonio Giovanni Richetta, Ugo Bottoni, Giovanni Paolino, Rita Clerico, Carmen Cantisani, Marina Ambrifi, Paola Corsetti, Stefano Calvieri

Research output: Contribution to journalArticle

Abstract

In the absence of risk factors, thin melanomas (TM) present a long-term survival; however, recurrences may occur. We describe the predictive clinicopathological features of patients with metastatic TM. Kaplan-Meier product was performed for the survival analysis, while Cox proportional hazards regression was used to evaluate the effect of the clinicopathological features on disease-free survival (DFS) and overall survival (OS). Median DFS of the entire cohort was 26 months and three patients developed late metastases. Nine patients developed extra-nodal metastases as first recurrence, while cases of positive sentinel lymph node biopsy (SLNB) were not found. DFS and OS varied according to the clinicopathological features, but only ulceration remained the main statistical significance value. According to our results, a hypothetical use of SLNB in TM without other risk factors is not currently feasible. No consensus exists as to which patients with TM are at risk for metastases or late recurrences.

Original languageEnglish
Article number909
JournalMedical Oncology
Volume31
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Melanoma
Disease-Free Survival
Recurrence
Sentinel Lymph Node Biopsy
Neoplasm Metastasis
Survival
Survival Analysis

Keywords

  • Late recurrences
  • Metastatses
  • Sentinel lymph node biopsy
  • Survival
  • Thin melanoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology
  • Medicine(all)

Cite this

Richetta, A. G., Bottoni, U., Paolino, G., Clerico, R., Cantisani, C., Ambrifi, M., ... Calvieri, S. (2014). Thin melanoma and late recurrences: It is never too thin and never too late. Medical Oncology, 31(4), [909]. https://doi.org/10.1007/s12032-014-0909-4

Thin melanoma and late recurrences : It is never too thin and never too late. / Richetta, Antonio Giovanni; Bottoni, Ugo; Paolino, Giovanni; Clerico, Rita; Cantisani, Carmen; Ambrifi, Marina; Corsetti, Paola; Calvieri, Stefano.

In: Medical Oncology, Vol. 31, No. 4, 909, 2014.

Research output: Contribution to journalArticle

Richetta, AG, Bottoni, U, Paolino, G, Clerico, R, Cantisani, C, Ambrifi, M, Corsetti, P & Calvieri, S 2014, 'Thin melanoma and late recurrences: It is never too thin and never too late', Medical Oncology, vol. 31, no. 4, 909. https://doi.org/10.1007/s12032-014-0909-4
Richetta AG, Bottoni U, Paolino G, Clerico R, Cantisani C, Ambrifi M et al. Thin melanoma and late recurrences: It is never too thin and never too late. Medical Oncology. 2014;31(4). 909. https://doi.org/10.1007/s12032-014-0909-4
Richetta, Antonio Giovanni ; Bottoni, Ugo ; Paolino, Giovanni ; Clerico, Rita ; Cantisani, Carmen ; Ambrifi, Marina ; Corsetti, Paola ; Calvieri, Stefano. / Thin melanoma and late recurrences : It is never too thin and never too late. In: Medical Oncology. 2014 ; Vol. 31, No. 4.
@article{61f705161c6e4fb38943bf5591172fbe,
title = "Thin melanoma and late recurrences: It is never too thin and never too late",
abstract = "In the absence of risk factors, thin melanomas (TM) present a long-term survival; however, recurrences may occur. We describe the predictive clinicopathological features of patients with metastatic TM. Kaplan-Meier product was performed for the survival analysis, while Cox proportional hazards regression was used to evaluate the effect of the clinicopathological features on disease-free survival (DFS) and overall survival (OS). Median DFS of the entire cohort was 26 months and three patients developed late metastases. Nine patients developed extra-nodal metastases as first recurrence, while cases of positive sentinel lymph node biopsy (SLNB) were not found. DFS and OS varied according to the clinicopathological features, but only ulceration remained the main statistical significance value. According to our results, a hypothetical use of SLNB in TM without other risk factors is not currently feasible. No consensus exists as to which patients with TM are at risk for metastases or late recurrences.",
keywords = "Late recurrences, Metastatses, Sentinel lymph node biopsy, Survival, Thin melanoma",
author = "Richetta, {Antonio Giovanni} and Ugo Bottoni and Giovanni Paolino and Rita Clerico and Carmen Cantisani and Marina Ambrifi and Paola Corsetti and Stefano Calvieri",
year = "2014",
doi = "10.1007/s12032-014-0909-4",
language = "English",
volume = "31",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press Inc.",
number = "4",

}

TY - JOUR

T1 - Thin melanoma and late recurrences

T2 - It is never too thin and never too late

AU - Richetta, Antonio Giovanni

AU - Bottoni, Ugo

AU - Paolino, Giovanni

AU - Clerico, Rita

AU - Cantisani, Carmen

AU - Ambrifi, Marina

AU - Corsetti, Paola

AU - Calvieri, Stefano

PY - 2014

Y1 - 2014

N2 - In the absence of risk factors, thin melanomas (TM) present a long-term survival; however, recurrences may occur. We describe the predictive clinicopathological features of patients with metastatic TM. Kaplan-Meier product was performed for the survival analysis, while Cox proportional hazards regression was used to evaluate the effect of the clinicopathological features on disease-free survival (DFS) and overall survival (OS). Median DFS of the entire cohort was 26 months and three patients developed late metastases. Nine patients developed extra-nodal metastases as first recurrence, while cases of positive sentinel lymph node biopsy (SLNB) were not found. DFS and OS varied according to the clinicopathological features, but only ulceration remained the main statistical significance value. According to our results, a hypothetical use of SLNB in TM without other risk factors is not currently feasible. No consensus exists as to which patients with TM are at risk for metastases or late recurrences.

AB - In the absence of risk factors, thin melanomas (TM) present a long-term survival; however, recurrences may occur. We describe the predictive clinicopathological features of patients with metastatic TM. Kaplan-Meier product was performed for the survival analysis, while Cox proportional hazards regression was used to evaluate the effect of the clinicopathological features on disease-free survival (DFS) and overall survival (OS). Median DFS of the entire cohort was 26 months and three patients developed late metastases. Nine patients developed extra-nodal metastases as first recurrence, while cases of positive sentinel lymph node biopsy (SLNB) were not found. DFS and OS varied according to the clinicopathological features, but only ulceration remained the main statistical significance value. According to our results, a hypothetical use of SLNB in TM without other risk factors is not currently feasible. No consensus exists as to which patients with TM are at risk for metastases or late recurrences.

KW - Late recurrences

KW - Metastatses

KW - Sentinel lymph node biopsy

KW - Survival

KW - Thin melanoma

UR - http://www.scopus.com/inward/record.url?scp=84895102435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895102435&partnerID=8YFLogxK

U2 - 10.1007/s12032-014-0909-4

DO - 10.1007/s12032-014-0909-4

M3 - Article

C2 - 24610543

AN - SCOPUS:84895102435

VL - 31

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 4

M1 - 909

ER -